Table 2.

Association results of five novel SNPs in Phase 1, Phase 2, and the Phase 1 + 2 meta-analysis

SNP	CHR:Position(bp)a	Geneb	Coded allele	Non-coded allele	Facial traits	Association results					Meta-analysis (Phase 1 + 2)
							AF	beta ± se	P-value		beta ± se	P-value	Q	I2
rs7567283	2:19,595,772	OSR1-WDR35	G	A	Right facial angle of en-ex-go	Phase 1	0.24	−0.572 ± 0.109	1.72 × 10−7		− 0.536 ± 0.096	2.75 × 10 −8	0.48	0.00
						Phase 2	0.24	− 0.410 ± 0.205	0.046
rs970797	2:176,820,065	HOXD1-MTX2	A	C	Tangent line angle of el3	Phase 1	0.33	0.017 ± 0.003	4.90 × 10 −8		0.015 ± 0.003	7.40 × 10 −9	0.29	12.52
						Phase 2	0.34	0.011 ± 0.005	0.030
					Tangent line angle of er3	Phase 1	0.33	0.015 ± 0.003	4.51 × 10−7		0.015 ± 0.003	3.97 × 10 − 9	0.93	0.00
						Phase 2	0.34	0.014 ± 0.005	0.003
rs3736712	6:169,699,889	WDR27	C	T	Eye tail length	Phase 1	0.37	0.322 ± 0.055	5.89 × 10 −9		0.293 ± 0.048	8.44 × 10 −10	0.30	6.92
						Phase 2	0.38	0.208 ± 0.095	0.029
rs2193054	17:67,537,404	SOX9	C	G	Profile nasal angle	Phase 1	0.47	−0.007 ± 0.001	1.43 × 10 −11		−0.007 ± 0.001	6.17 × 10 − 17	0.22	33.67
						Phase 2	0.46	−0.009 ± 0.002	4.60 × 10− 7
					Nasal tip protrusion	Phase 1	0.47	0.019 ± 0.003	1.93 × 10 −8		0.017 ± 0.003	5.34 × 10 −9	0.23	31.80
						Phase 2	0.46	0.011 ± 0.005	0.050
rs2206437	20:37,426,155	DHX35	A	T	Subnasal width	Phase 1	0.26	−0.272 ± 0.054	4.75 × 10− 7		− 0.283 ± 0.047	1.61 × 10 −9	0.69	0.00
						Phase 2	0.28	− 0.316 ± 0.095	8.67 × 10−4

Bold and underlined text indicates genome-wide significant P values (5 × 10⁻⁸)

CHR chromosome, AF coded allele frequency, Q P-value for Cochrane’s Q statistic, I² heterogeneity index

^aPositions according to NCBI Build 36

^bGenes are defined as the gene within the SNP locates or genes closest to the SNP within a ±400-kb window when the SNP dose not locate within a gene